तुलना करने के लिए मीट्रिक्स | CFRXQ | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCFRXQपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.2x | −0.4x | |
PEG अनुपात | 0.00 | 0.03 | 0.00 | |
क़ीमत/बुक | 0.0x | −1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 96.9x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 795.5% | 57.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.3% | 7.7% | अनलॉक करें |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.